Incyte's Phase 3 Retifanlimab Anal Cancer Trial Listed as Completed
The POD1UM-303/InterAACT 2 study of retifanlimab added to carboplatin-paclitaxel in advanced anal cancer now carries COMPLETED status on ClinicalTrials.gov.
ClinicalTrials.gov record NCT04472429 lists Incyte Corporation's Phase 3 study as COMPLETED, with the entry last updated 2 September 2026.
The trial tested carboplatin-paclitaxel with retifanlimab or placebo in locally advanced or metastatic squamous cell anal carcinoma.
The study is identified as POD1UM-303/InterAACT 2; the indication is squamous cell carcinoma of the anal canal.
The registry entry reports status only and contains no efficacy, safety or regulatory outcome data.
This is a factual summary of a public filing or press release, not investment advice. Verify all figures against the source before acting on them.
